These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 21205967

  • 1. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
    Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell'Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM.
    JAMA; 2011 Jan 05; 305(1):59-67. PubMed ID: 21205967
    [Abstract] [Full Text] [Related]

  • 2. A large fraction of trisomy 12, 17p-, and 11q- CLL cases carry unidentified microdeletions of miR-15a/16-1.
    Pepe F, Rassenti LZ, Pekarsky Y, Labanowska J, Nakamura T, Nigita G, Kipps TJ, Balatti V, Croce CM.
    Proc Natl Acad Sci U S A; 2022 Jan 25; 119(4):. PubMed ID: 35064090
    [Abstract] [Full Text] [Related]

  • 3. microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia.
    Deneberg S, Kanduri M, Ali D, Bengtzen S, Karimi M, Qu Y, Kimby E, Mansouri L, Rosenquist R, Lennartsson A, Lehmann S.
    Epigenetics; 2014 Jun 25; 9(6):910-7. PubMed ID: 24686393
    [Abstract] [Full Text] [Related]

  • 4. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S.
    Blood; 2009 Sep 24; 114(13):2589-97. PubMed ID: 19643983
    [Abstract] [Full Text] [Related]

  • 5. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
    Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MH, Mertens D, Döhner H, Stilgenbauer S.
    Blood; 2009 Apr 16; 113(16):3801-8. PubMed ID: 18941118
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Karyotype-specific microRNA signature in chronic lymphocytic leukemia.
    Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, Volinia S, Ferracin M, Palatini J, Balatti V, Alder H, Negrini M, Kipps TJ, Croce CM.
    Blood; 2009 Oct 29; 114(18):3872-9. PubMed ID: 19717645
    [Abstract] [Full Text] [Related]

  • 8. Role of miR-15/16 in CLL.
    Pekarsky Y, Croce CM.
    Cell Death Differ; 2015 Jan 29; 22(1):6-11. PubMed ID: 24971479
    [Abstract] [Full Text] [Related]

  • 9. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S, López A, Rasillo A, Sayagués JM, Barrena S, Sánchez ML, Teodosio C, Giraldo P, Giralt M, Pérez MC, Romero M, Perdiguer L, Orfao A.
    Cytometry B Clin Cytom; 2008 May 29; 74(3):139-49. PubMed ID: 18061951
    [Abstract] [Full Text] [Related]

  • 10. TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
    Balatti V, Rizzotto L, Miller C, Palamarchuk A, Fadda P, Pandolfo R, Rassenti LZ, Hertlein E, Ruppert AS, Lozanski A, Lozanski G, Kipps TJ, Byrd JC, Croce CM, Pekarsky Y.
    Proc Natl Acad Sci U S A; 2015 Feb 17; 112(7):2169-74. PubMed ID: 25646413
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
    Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM.
    Cancer Res; 2006 Dec 15; 66(24):11590-3. PubMed ID: 17178851
    [Abstract] [Full Text] [Related]

  • 17. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
    Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A, Kröber A, Jäger U, Lichter P, Döhner H, Stilgenbauer S.
    J Clin Oncol; 2005 Jun 01; 23(16):3780-92. PubMed ID: 15867199
    [Abstract] [Full Text] [Related]

  • 18. Interphase fluorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. a study of 40 early-onset patients.
    Doneda L, Montillo M, Intropido L, Tedeschi A, Morra E, Larizza L.
    Cancer Genet Cytogenet; 2003 Jan 01; 140(1):31-6. PubMed ID: 12550755
    [Abstract] [Full Text] [Related]

  • 19. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.
    Mohr J, Helfrich H, Fuge M, Eldering E, Bühler A, Winkler D, Volden M, Kater AP, Mertens D, Te Raa D, Döhner H, Stilgenbauer S, Zenz T.
    Blood; 2011 Feb 03; 117(5):1622-32. PubMed ID: 21115975
    [Abstract] [Full Text] [Related]

  • 20. Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.
    Wang LQ, Kwong YL, Wong KF, Kho CS, Jin DY, Tse E, Rosèn A, Chim CS.
    J Transl Med; 2014 Feb 22; 12():52. PubMed ID: 24559316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.